Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04251117 · ClinicalTrials.gov registry record · Phase 1
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC
A Phase 1 study of HCC, sponsored by Geneos Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 3
- Study locations
NCT04251117: Active Phase 1 study of HCC, sponsored by Geneos Therapeutics.
NCT04251117 is a Phase 1 study of HCC that is active but no longer recruiting, run by Geneos Therapeutics. The registered enrollment target is 36 participants, below the 199-participant average among 13 other HCC trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04251117, a Phase 1 study of HCC, is active but no longer recruiting, sponsored by Geneos Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- BIOLOGICAL INO-9012
- BIOLOGICAL GNOS-PV02
- DEVICE CELLECTRA®2000 EP Device
Study Locations (3)
Maryland
- Johns Hopkins Hospital - Baltimore
New York
- Icahn School of Medicine at Mount Sinai - New York
Other
- Auckland Clinical Studies - Auckland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2028-11-29 |
| Phase | Phase 1 |
What the registry record for NCT04251117 still lists
NCT04251117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 199-participant average among 13 other HCC trials with a reported enrollment target (82% lower).
The record links to 1 condition, with HCC appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT04251117 reports a single indexed study location in Maryland, New York, Other.
Frequently Asked Questions
What is clinical trial NCT04251117 about?
NCT04251117 is a clinical study titled "GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC". This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report.
What is the current status of trial NCT04251117?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2020-03-01. Estimated completion is 2028-11-29.
What conditions does trial NCT04251117 study?
This clinical trial studies the following conditions: HCC.
What interventions are being tested in trial NCT04251117?
The interventions under investigation include: Pembrolizumab (DRUG), INO-9012 (BIOLOGICAL), GNOS-PV02 (BIOLOGICAL), CELLECTRA®2000 EP Device (DEVICE).
Who is sponsoring clinical trial NCT04251117?
This trial is sponsored by Geneos Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04251117 being conducted?
This trial has 3 study locations across Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HCC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04251117's enrollment target sits among peer trials
36 10th of 13 higher than 4 of 13 other HCC trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HCC trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC
RECRUITING · Phase 1
-
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
COMPLETED · Phase 1
-
Multi-analyte Blood Test Clinical Trial
RECRUITING
-
HOPE Against Cancer Recurrence in HCC
RECRUITING · Phase 4
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
Y-90 Treatment Response Using Transarterial Radioembolization
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI